Bolt Biotherapeutics, Inc. Marketable Securities, Unrealized Gain (Loss)
Bolt Biotherapeutics, Inc. (BOLT) reported Marketable Securities, Unrealized Gain (Loss) of $321.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2022-03-30
- Bolt Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2021-12-31 was $283.00K.
- Bolt Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2021-09-30 was $15.00K.
- Bolt Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2021-06-30 was -$41.00K.
- Bolt Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2021-03-31 was $64.00K, a 540.00% increase year-over-year.
- Bolt Biotherapeutics, Inc. marketable securities, unrealized gain (loss) for fiscal 2021 was $321.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2021-12-31 | $283.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $298.00K derived: sum of 2 quarters · filed 2022-03-30 | $257.00K derived: sum of 3 quarters · filed 2022-03-30 | $321.00K 10-K · filed 2022-03-30 |
| 2021-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$26.00K derived: sum of 2 quarters · filed 2021-11-09 | $38.00K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | -$41.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $23.00K 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $64.00K 10-Q · filed 2021-05-13 | |||
| 2020-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$12.00K derived: sum of 2 quarters · filed 2021-11-09 | -$2.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$1.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $10.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |